UICC World Cancer Congress 2006

Methods: LE treatment was administered to 145 patients. Non-persistent and segmentary edema with the extremity volume increase up to 25% was classified as mild grade LE (81 patients), persistent edema without indurative changes in derma and muscles – as moderate (64). Latent LE period varied from 3 months to 16 years. The duration of clinically manifested edema before the start of the treatment was 15 months on the average. Eighty patients were treated with Cyclo-3 Fort, 3 capsules daily for 90 days. Sixty-five patients received two courses of arm pneumocompression and magnetoinductive stimulation of shoulder girdle muscles on the LE side at 1-2-month intervals with concurrent administration of Cyclo-3 Fort at the above doses. Reduction of the edema was assessed on the 30th, 60th and 90th day of the treatment.

Results: Reduction of the edema and its complete resorption occurred in 85% of patients administered medicinal treatment and 91% of those managed physicomedicinally. Medium reduction of the edema at the end of the treatment amounted to 58% and 76% of the excessive volume respectively. No significant advantages of physicomedicinal treatment over medicinal one were found for mild grade edema. Thus, effective Cyclo-3 Fort monodrug therapy is feasible for mild grade LE. The inclusion of pneumatic compression and magnetoinductive stimulation of muscles into the treatment scheme of moderate grade LE increases the extent of edema reduction 1.8-fold compared to medicinal therapy (70% and 39% respectively, p<0,05).